Table 1 Baseline characteristics of the cohort
From: Clinical baseline factors predict response to natalizumab: their usefulness in patient selection
Number of MS patients | 62 |
|---|---|
Sex | 43 F, 19 M (69.4%–30.6%) |
Age, mean (range) | 37.5 years (20–60) |
Disease duration, mean (range) | 8.89 years (0–32) |
ARR previous year (range) | 2.26 (0–6) |
ARR previous year, categorized | 0-1 relapse: N = 21; 2 relapses, N = 22; ≥ 3 relapses, N = 19 |
Mean EDSS gain in the year before | +0.41 (SD 1.26)* |
Mean baseline EDSS | 4.1 (range 0–7.5) |
Baseline EDSS, categorized | EDSS 0–2.5, N = 16; EDSS 3.0–3.5: N = 15, EDSS 4.0-5.5: N = 15, EDSS ≥6.0:, N = 16 |